Bone and dentin tissue

Bone and dentin tissue refers to the mineralized extracellular matrices that provide structural integrity to the skeletal system and teeth (StatPearls, 2023 [1]). These tissues are composed of an organic framework, predominantly Type I collagen, and an inorganic component consisting of hydroxyapatite crystals (PubMed, 2020 [2]). While 'bone and dentin tissue' is a physiological structure rather than a single molecular target, it serves as the therapeutic site for numerous drugs aimed at treating metabolic bone diseases and dental conditions (NIH, 2022 [3]). Pharmacological interventions typically target the cellular components within these tissues—such as osteoblasts, osteoclasts, and odontoblasts—or the mineral phase itself to regulate bone remodeling and mineralization (PubChem, 2024 [4]). For instance, bisphosphonates bind directly to the hydroxyapatite mineral to inhibit bone resorption, while biologics like denosumab target signaling proteins that regulate bone-resorbing cells (PubMed, 2021 [9]). In the context of dentin, therapeutic efforts often focus on regenerative medicine to stimulate odontoblasts and promote reparative dentin formation (PubMed, 2018 [12]). Disorders affecting these tissues include osteoporosis, where bone mass is lost, and dentinogenesis imperfecta, which affects tooth structure and strength (MedlinePlus, 2021 [5]).

Other names

Mineralized tissueHard tissueCalcified tissueMineralized extracellular matrix

Drugs targeting these tissues work by binding to hydroxyapatite crystals to inhibit osteoclast-mediated resorption (e.g., bisphosphonates) (PubChem, 2024 [4]), modulating osteoblast/osteoclast signaling pathways such as RANKL or Sclerostin inhibition (PubMed, 2021 [9]), or promoting mineral deposition and odontoblast activity (PubMed, 2018 [12]).